MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: Controversy Over Prostate Cancer Screening

Back to prostate Blogs list Cancer blog  


Subscribe To Prostate RSS Feed  RSS content feed What is RSS feed?






Controversy Over Prostate Cancer Screening

Controversy Over Prostate Cancer Screening John Concato, M.D.
A screening test for prostate cancer that measures prostate-specific antigen (PSA) levels does not improve survival, scientists at the Veterans Affairs (VA) Connecticut Healthcare System and Yale School of Medicine report in the January 9 Archives of Internal Medicine.

Prostate cancer is the most common cancer affecting American men and ranks second in mortality. According to the study, screening tests almost always increase the detection of cancer, but among other requirements for improving survival, the tumors detected must be both fatal (if left untreated) yet curable.

PSA, a protein produced in the prostate, is found in the blood of healthy men. Prostate cancer often increases PSA levels in the blood, but a similar increase can be caused by non-malignant enlargement of the prostate gland (prostatism) or prostate infections.

To test the impact of prostate cancer screening on survival, the scientists conducted a case-control review of the medical records of over 1,000 male veterans age 50 or older receiving care at 10 VA medical centers in New England. Half of the men had died with prostate cancer; the other half were living and matched to be the same age as those who died. The study included up to nine years of follow-up after the diagnosis of cancer. The scientists compared the group that died to the group that lived and found that the same fraction of men had received screening with the PSA test.

"This study suggests that screening was not effective," said first author John Concato, M.D., associate professor of medicine at Yale School of Medicine and director of the Clinical Epidemiology Research Center at the VA Connecticut Healthcare System. "If screening worked, men who died would have had less testing than those who lived."

Concato and his team also determined that digital rectal examinations along with PSA did not improve survival.

"Unfortunately, screening tests can sometimes find cancer, even at early stages, but not prolong survival," said Concato, who is also a member of the Yale Cancer Center. "Rather than encouraging annual screening of all men starting at age 50, as is usually done, the limited effectiveness of PSA testing should be explained to patients in the process of obtaining their informed consent to the test."

The study was supported by funding from the Department of Veterans Affairs.

Other authors on the study included Carolyn K. Wells, Ralph I. Horwitz, M.D., David Penson, M.D., Graeme Fincke, M.D., Dan R. Berlowitz, M.D., Gregory Froehlich, M.D., Dawna Blake, M.D., Martyn A. Vickers, M.D., Gerald A. Gehr, M.D., Nabil H. Raheb, M.D., and Peter Peduzzi.

Citation: Archives of Internal Medicine, Vol. 166 (January 9, 2006).

Posted By: Mark




Did you know?
A screening test for prostate cancer that measures prostate-specific antigen (PSA) levels does not improve survival, scientists at the Veterans Affairs (VA) Connecticut Healthcare System and Yale School of Medicine report in the January 9 Archives of Internal Medicine. Prostate cancer is the most common cancer affecting American men and ranks second in mortality. According to the study, screening tests almost always increase the detection of cancer, but among other requirements for improving survival, the tumors detected must be both fatal (if left untreated) yet curable.

Medicineworld.org: Controversy Over Prostate Cancer Screening

Comprehensive| Diagnosis of bladder cancer| Follow up of bladder cancer| Bladder cancer main| Overview of bladder cancer| Risk factors for bladder cancer| Screening for bladder cancer| Symptoms of bladder cancer| Treatment of bladder cancer|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.